PE20120323A1 - Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib - Google Patents

Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib

Info

Publication number
PE20120323A1
PE20120323A1 PE2011001907A PE2011001907A PE20120323A1 PE 20120323 A1 PE20120323 A1 PE 20120323A1 PE 2011001907 A PE2011001907 A PE 2011001907A PE 2011001907 A PE2011001907 A PE 2011001907A PE 20120323 A1 PE20120323 A1 PE 20120323A1
Authority
PE
Peru
Prior art keywords
sorafenib
trimetoxifenil
phenil
serinamide
metoxy
Prior art date
Application number
PE2011001907A
Other languages
English (en)
Inventor
Brigitte Dermes
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20120323A1 publication Critical patent/PE20120323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMBINACION FARMACEUTICA ANTITUMORAL QUE COMPRENDE: A) AVE8062 DE FORMULA (I) EN FORMA DE HIDROCLORURO; Y B) SORAFENIB EN FORMA DE TOSILATO; EN DONDE EL AVE8062 SE ADMINISTRA POR VIA PARENTERAL Y ANTES QUE EL SORAFENIB EL CUAL SE ADMINISTRA POR VIA ORAL. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE TUMOR SOLIDO, SARCOMA, CANCER DE PULMON, CANCER DE OVARIO, CANCER DE RINON
PE2011001907A 2009-05-07 2010-05-06 Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib PE20120323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
PE20120323A1 true PE20120323A1 (es) 2012-04-17

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001907A PE20120323A1 (es) 2009-05-07 2010-05-06 Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014732A (es) * 2010-06-18 2013-01-22 Sanofi Sa Una combinacion antitumoral que comprende ombrabulina un derivado de taxano y un derivado de platino.
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
WO2015126903A1 (en) * 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ATE328599T1 (de) * 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
CN101816794A (zh) * 2001-06-25 2010-09-01 味之素株式会社 抗肿瘤剂
EP1474393A1 (en) * 2002-02-11 2004-11-10 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
FR2945210A1 (fr) 2010-11-12
CO6390102A2 (es) 2012-02-29
TN2011000551A1 (fr) 2013-05-24
EA201171366A1 (ru) 2012-05-30
BRPI1014197A2 (pt) 2016-04-26
CN102438608A (zh) 2012-05-02
WO2010128259A1 (fr) 2010-11-11
UY32618A (es) 2010-12-31
NI201100191A (es) 2012-01-16
MA33346B1 (fr) 2012-06-01
CR20110573A (es) 2011-12-08
CA2761146A1 (fr) 2010-11-11
TW201043225A (en) 2010-12-16
FR2945210B1 (fr) 2011-07-01
DOP2011000335A (es) 2011-12-15
MX2011011767A (es) 2012-02-28
US20120108641A1 (en) 2012-05-03
ZA201108110B (en) 2013-01-30
AU2010244254A1 (en) 2011-11-24
CL2011002782A1 (es) 2012-03-30
KR20120023754A (ko) 2012-03-13
SG175895A1 (en) 2011-12-29
IL216133A0 (en) 2012-01-31
AR076848A1 (es) 2011-07-13
ECSP11011440A (es) 2011-12-30
JP2012526090A (ja) 2012-10-25
EP2427185A1 (fr) 2012-03-14

Similar Documents

Publication Publication Date Title
PE20120323A1 (es) Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2012012571A (es) Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas.
BR112014012407A2 (pt) amidas de piridona e análogos exibindo propriedades anti-câncer e anti-proliferativas
PE20151654A1 (es) Inhibidores de cdc7
CO6592104A2 (es) Compuesto heterociclico
AR077629A1 (es) Mimetico de smac
AR100006A1 (es) Derivados de tubulisina
BR112015022430B8 (pt) Transportador separador
CR20140301A (es) Derivados de betulina
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
PA8850801A1 (es) Compuestos útiles para inhibir chk1
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2008001213A1 (es) Uso de compuestos derivados de piridin-4-il-benceno-1,4-diamino sustituidos por alquindol para preparar un medicamento para el tratamiento de un trastorno proliferativo tal como el cancer.
AR062391A1 (es) Uso de compuestos y derivados de 2,5 dihidroxibenceno para el tratamiento de dicracias hematologicas y cancer de un organo
NZ722345A (en) Pyrazolone compounds and uses thereof
PE20150904A1 (es) Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos
EA027986B9 (ru) Соединения триазолона и их применение
AR091764A1 (es) Derivados de ariletinilo
AR092627A1 (es) Derivados glucopiranosidos de urea
AR092673A1 (es) Derivados de ariletinilo

Legal Events

Date Code Title Description
FC Refusal